Clue to Aspirin, Colon Cancer Link; New Lutathera Approval; AI & Electronic Records

[MEDPAGE TODAY]( Oncology Update Friday, April 26, 2024 [Clue to Aspirin, Colon Cancer Link; New Lutathera Approval; AI & Electronic Records]( [High Deep-Remission Rate With Triple Regimen for Relapsed/Refractory CLL]( [ESR1-Driven Resistance to CDK4/6 Inhibitors in Breast Cancer Thwarted by SERDs]( [FDA OKs Second Gene Therapy for Hemophilia B]( [Quadruplet Shows 'Excellent Activity' in Myeloma Patients Who Defer HSCT]( ADVERTISEMENT Exclusives & Features [Are We Testing Enough for H5N1?]( [Doc Writes Book With ChatGPT; Can AI Detect STIs? How AI Replies to Patient Messages]( [NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.]( PURPOSE: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet... [READ MORE]( [CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers]( A strategy of sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and haploidentical hematopoietic stem-cell transplantation (HSCT), without graft-versus-host disease (GVHD) prophylaxis, is... [READ MORE]( [Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.]( Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the... [READ MORE]( [Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis.]( BACKGROUND: The addition of pembrolizumab (pembro) to neoadjuvant chemotherapy (NAC) is standard of care for the treatment of early triple-negative breast cancer (TNBC) after KEYNOTE-522 trial... [READ MORE]( [NICE gives green light to life-extending drug combo for brain cancer | Nursing Times]( Children and teenagers with an aggressive form of brain cancer are set to benefit from a new life-extending drug combination. Read more.  Children and teenagers with an aggressive form of brain... [READ MORE]( [A Property of Everyday Health group]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Spec_Oncology_Update?xid=nl_mpt_Oncology_update_2024-04-26&mh=3c4cdd242849aa0e970f25e401732f81) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011